Continental Chemicals reports no deviation in preferential issue fund utilization

Continental Chemicals Limited has submitted a statement of deviation under Regulation 32 of the SEBI (LODR) Regulations, 2015, confirming that there has been no variation in the utilization of funds raised through its preferential issue for the quarter ended June 30, 2026. The filing indicates that the company strictly adhered to the originally disclosed objects for the funds, which were designated for working capital requirements, with no deviations or variations reported during the period.

The regulatory submission, dated August 11, 2026, and signed by Company Secretary Sakshi Dhawan, provides transparency regarding the status of the capital raised on October 14, 2019. According to the annexure attached to the filing, the total amount raised was ₹1,62,50,000. The document explicitly states that the funds have been fully utilized in the quarter ended December 31, 2023, meaning no further utilization or deviation occurred in the subsequent quarters, including the current reporting period.

The audit committee of Continental Chemicals reviewed and approved the statement, affirming compliance with the regulatory requirements. No monitoring agency was appointed for this specific fundraising activity, as indicated in the filing. Furthermore, there were no comments from auditors regarding any irregularities or deviations, reinforcing the clean status of the fund utilization.

Fund Utilization Details	Status
Mode of Fund Raising	Preferential Issues
Date of Raising Funds	October 14, 2019
Total Amount Raised	₹1,62,50,000
Original Object	Working Capital
Modified Object	Not Applicable
Deviation/Variation	No
Amount of Deviation	₹0

The filing clarifies that a deviation or variation could imply changes in the objects for which funds were raised, discrepancies in the amount utilized versus what was disclosed, or changes in contract terms. None of these scenarios applied to Continental Chemicals’ recent reporting. The company’s managing director, Naresh Kumar Chibba, also endorsed the document, ensuring executive accountability for the disclosure.

What the Numbers Show

The complete utilization of the ₹1,62,50,000 by December 31, 2023, suggests that the working capital needs associated with this specific fundraising event were met within approximately four years of the capital raise. With zero deviation recorded in Q1FY26, the company demonstrates disciplined adherence to its initial funding objectives, eliminating any regulatory concerns regarding misallocation or unauthorized use of investor capital for this particular tranche.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
0.0%	+3.48%	-3.37%	-29.70%	-16.67%	-23.73%

Continental Chemicals Limited reported a net profit of ₹11.54 lakh for the first quarter of FY27 (Q1FY27), ending June 30, 2026, marking a 20% decline from ₹14.41 lakh in the same period last year. Total revenue from operations stood at ₹42.67 lakh, a slight decrease from ₹43.88 lakh in Q4FY26, while earnings per share (basic and diluted) fell to ₹0.51 from ₹0.64 in Q1FY26. The Board of Directors approved the unaudited financial results during a meeting held on August 11, 2026, at its registered office in Noida.

The company’s profitability remains heavily influenced by non-operating income streams rather than core operational revenue. While 'Revenue from Operations' is listed at ₹574 lakh, this figure appears anomalous given the 'Total Revenue' line item of ₹42.67 lakh and negligible cost of materials consumed. Other income contributed ₹36.93 lakh, forming the bulk of the top line. Expenses totaled ₹29.92 lakh, up from ₹24.49 lakh in Q1FY26, driven by higher employee benefits expense of ₹14.25 lakh and increased other expenditure of ₹10.83 lakh.

Financial Performance Highlights

Particulars	Q1FY27 (₹ lakh)	Q4FY26 (₹ lakh)	Q1FY26 (₹ lakh)	FY26 (₹ lakh)
Revenue from Operations	574.00	7.46	5.81	25.52
Other Income	36.93	36.42	34.95	142.28
Total Revenue	42.67	43.88	40.76	167.80
Employee Benefits Expense	14.25	10.79	14.33	54.16
Finance Cost	1.15	1.06	1.08	4.27
Depreciation & Amortisation	3.69	5.41	2.92	11.96
Other Expenditure	10.83	13.11	6.16	38.65
Total Expenses	29.92	30.37	24.49	109.04
Profit Before Tax	12.75	13.51	16.27	58.76
Tax Expense	1.21	1.71	1.86	7.55
Net Profit	11.54	11.80	14.41	51.21

What the Numbers Show

The divergence between the 'Revenue from Operations' line item (₹574 lakh) and the 'Total Revenue' figure (₹42.67 lakh) suggests that the higher revenue figure may include non-operating items or requires clarification through further disclosure notes not fully expanded in the summary table. Given that other income remained steady at ₹36.93 lakh, the bulk of the total revenue appears derived from this source rather than core operations, which were negligible in the prior comparable period (₹5.81 lakh). This structure indicates that the company’s profitability remains heavily influenced by non-operating income streams.

Regulatory Compliance

The limited review report was issued by SSVS & Co., Chartered Accountants, with Vipul Sharma as the partner. The review was conducted in accordance with Standard on Review Engagement (SRE) 2410. The financial results were prepared in compliance with Ind AS 34 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. No dividend was declared for the quarter.